There are currently 992 clinical trials in Tampa, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Moffitt Cancer Center, University of South Florida, H. Lee Moffitt Cancer Center and Research Institute and Tampa General Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)
NCT06235281
Recruiting
This is an open label, single arm, single-center, pilot study of concurrent phototherapy and POTELIGEO (mogamulizumab-kpkc) in early-stage mycosis fungoides.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Mycosis Fungoides
Register for Updates
Global Study of Del-desiran for the Treatment of DM1
NCT06411288
Recruiting
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1
Gender:
ALL
Ages:
Between 16 years and 65 years
Trial Updated:
05/21/2025
Locations: University Research Center of South Florida, Tampa, Florida
Conditions: DM1, Myotonic Dystrophy, Myotonic Dystrophy 1, Myotonia, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Steinert, Myotonic Muscular Dystrophy
Register for Updates
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
NCT06501196
Recruiting
Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R AML) or higher-risk myelodysplastic syndrome (HR-MDS). Phase 1 (Dose Escalation) will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of BH-30236 administered orally. Approximately 50 participants may be enrolled in Phase 1 of the study. Phase 1b (Dose Expansion... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Preleukemia, Myelodysplastic Syndromes, Refractory Acute Myeloid Leukemia
Register for Updates
Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
NCT06511882
Recruiting
The purpose of this research study is to see if people whose Acute myeloid leukemia (AML) is being successfully treated with azacitidine or decitabine in combination with venetoclax can discontinue this chemotherapy for some period of time after a year of treatment without increasing the likelihood that their AML will return.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Acute Myeloid Leukemia
Register for Updates
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
NCT06855212
Recruiting
The purpose of the study is to determine if cemiplimab in combination with cetuximab given before their surgery are beneficial and safe in participants with head and neck squamous cell carcinoma (HNSCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
NCT04155034
Recruiting
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma
Register for Updates
DASH INtervention to INvestigate the Gut
NCT04538482
Recruiting
The study investigators will recruit a generally healthy sample of 112 black and white adults from Birmingham, AL to participate in a 28-day randomized, controlled feeding study. Participants will be randomized to receive either the DASH diet or a standard American diet. All meals will be provided by the study. Fecal samples will be collected at multiple time points before, during, and after the dietary intervention and will be analyzed using PCR to amplify the V4 region of the 16S rRNA gene and... Read More
Gender:
ALL
Ages:
Between 19 years and 65 years
Trial Updated:
05/20/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Microbiota, Cancer
Register for Updates
Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML
NCT05024552
Recruiting
This study combines vyxeos and gilteritinib in patients with relapsed or refractory FLT3-mutated acute myeloid leukemia. Vyxeos and gilteritinib will be given as induction therapy. Those patients entering a complete remission or a complete remission with incomplete blood count recovery will be allowed to proceed to consolidation therapy with vyxeos and gilteritinib. Those patients who do not proceed to an allogeneic stem cell transplant for any reason are able to enter the maintenance phase of t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Acute Myeloid Leukemia With FLT3/ITD Mutation
Register for Updates
Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer
NCT05316129
Recruiting
The purpose of this first in human study is to evaluate the safety of treatment with autologous T cells genetically modified to express a CER (chimeric endocrine receptor) targeting the FSHR (follicle-stimulating hormone receptor) (FSHCER T cells), with or without conditioning chemotherapy, in participants with recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Ovarian Cancer
Register for Updates
A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab
NCT05388474
Recruiting
The virological efficacy of ibalizumab has been clearly demonstrated in multiple clinical trials. This study will expand ibalizumab's clinical data set and allow a better understanding of the virologic response durability on ARV regimens with or without ibalizumab in a heterogeneous real-world patient population. Additional data on the efficacy and safety of ibalizumab and its impact on patient reported outcomes will be captured until study end. Primary Objective: To evaluate the long-term eff... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Can Community Health, Tampa, Florida +2 locations
Conditions: HIV Infections, Multi-Antiviral Resistance
Register for Updates
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
NCT05850234
Recruiting
This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Research Site, Tampa, Florida
Conditions: Relapsed/ Refractory Multiple Myeloma
Register for Updates
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
NCT06714591
Recruiting
The objective of this study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Relapsed/Refractory Acute Myeloid Leukemia
Register for Updates